AXIM Biotechnologies, Inc. has started manufacturing its cannabinoid-based chewing gum with dronabinol, a synthetic THC form. The announcement was made by Medical Marijuana, Inc (MJNA) the first U.S. Company to process the world's first nutraceutical products. MJNA was also the first company to trade cannabis publicly. AXIM is also MJNA's major Investment Company.
AXIM's upcoming studies on cannabis in the treatment of chemotherapy-related symptoms intend to use the chewing gum, manufactured through its contract manufacturer, Eurofins Amatsigroup, in Belgium.
Center for Disease Control and Prevention observed that about 650,000 U.S. cancer patients undergo chemotherapy, spending 100,000 dollars annually. Symptoms attributed to chemotherapy patients include weakened immune system, nausea, and diarrhea.
Medical Marijuana, Inc. CEO Dr. Stuart Titus said the company supports AXIM in research, to assist those who are in need of innovative delivery mechanisms. He urged that the findings on dronabinol chewing gum will help those who undergo chemotherapy.
AXIM aims to conduct a study on dronabinol and FDA-approved capsules. The study will approve the use of dronabinol chewing gum rather than the use of oral ingestion in the treatment of chemotherapy symptoms.
John W. Huemoeller II, CEO, AXIM Biotech described how human delivery mechanism allows the intake of the product into the body via the oral mucosa, past the liver enabling bioavailability. He said the studies would show the composition of dronabinol gum to that of THC-approved products.